Vesleteplirsen - Sarepta Therapeutics
Alternative Names: SRP 5051Latest Information Update: 11 Mar 2024
Price :
$50 *
At a glance
- Originator Sarepta Therapeutics
- Class Antisense oligonucleotides; Morpholines; Peptide drug conjugates; Peptides
- Mechanism of Action Dystrophin expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Duchenne muscular dystrophy
Most Recent Events
- 11 Mar 2024 Serepta Therapeutics plans to meet FDA to discuss next steps related to 5051-201 trial in second half of 2024.
- 29 Jan 2024 Safety and efficacy data from part B of phase II MOMENTUM trial in Duchenne muscular dystrophy released by Sarepta Therapeutics
- 02 May 2023 Sarepta Therapeutics plans accelerated approval of vesleteplisen for Duchenne muscular dystrophy